HeartBeam Inc. (NASDAQ: BEAT) announced a strategic reorganization aimed at accelerating execution, expanding global market reach and improving capital efficiency as it advances commercialization of its cardiac monitoring technology. Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams designed to streamline decision-making, improve accountability and reduce costs. As part of the transition, former CEO Robert Eno will move into a consulting role.
The company said its strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection. HeartBeam also plans to expand partnerships with governments, health systems, ECG manufacturers and wearable device companies, building on its December 2025 FDA clearance for its synthesized 12-lead ECG technology for arrhythmia assessment.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.
The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement. For more details on the intended use of its technology, refer to the company’s Cleared Indications for Use at https://www.heartbeam.com/indications.
The reorganization positions HeartBeam to more efficiently execute its commercialization strategy, which includes leveraging its recently cleared technology to capture market share in the cardiac monitoring space. By focusing on partnerships with key stakeholders, the company aims to accelerate adoption of its 3D ECG platform and expand its footprint globally. The shift in leadership and operational structure is designed to reduce costs and improve accountability, key factors as the company moves from development to commercial stage.
This announcement underscores HeartBeam’s commitment to transforming cardiac care through innovative technology that enables early detection and monitoring of heart conditions outside traditional clinical settings. The company’s progress in securing FDA clearances and building a robust patent portfolio positions it as a potential leader in the portable ECG market.
